Juan Pablo López-Cervantes, Vivi Schlünssen, Chamara Senaratna, Simone Accordini, Francisco Javier Callejas, Karl A Franklin, Mathias Holm, Nils Oskar Jogi, Andrei Malinovschi, Anna Oudin, Torben Sigsgaard, Elin Helga Thorarinsdottir, Christer Janson, Randi Jacobsen Bertelsen, Cecilie Svanes
{"title":"Use of oral moist tobacco (snus) in puberty and its association with asthma in the population-based RHINESSA study.","authors":"Juan Pablo López-Cervantes, Vivi Schlünssen, Chamara Senaratna, Simone Accordini, Francisco Javier Callejas, Karl A Franklin, Mathias Holm, Nils Oskar Jogi, Andrei Malinovschi, Anna Oudin, Torben Sigsgaard, Elin Helga Thorarinsdottir, Christer Janson, Randi Jacobsen Bertelsen, Cecilie Svanes","doi":"10.1136/bmjresp-2024-002401","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the association of early snus use initiation (≤15 years of age) with asthma and asthma symptoms.</p><p><strong>Design: </strong>Cross-sectional analysis of a population-based cohort.</p><p><strong>Setting: </strong>Study centres in Norway, Sweden, Iceland, Denmark and Estonia, from 2016 to 2019.</p><p><strong>Participants: </strong>9002 male and female participants above 15 years of age of the Respiratory Health in Northern Europe, Spain and Australia study.</p><p><strong>Main outcome measures: </strong>Current asthma and asthma symptoms.</p><p><strong>Results: </strong>The median age of study participants was 28 years (range 15-53) and 58% were women. 20% had used snus, 29% men and 14% women. Overall, 26% of males and 14% of females using snus started ≤15 years of age. Early snus use initiation was associated with having three or more asthma symptoms (OR 2.70; 95% CI 1.46 to 5.00) and a higher asthma symptom score (β-coefficient (β) 0.35; 95% CI 0.07 to 0.63) in women. These associations were weak in men (OR 1.23; 95% CI 0.78 to 1.94; β 0.16; 95% CI -0.06 to 0.38, respectively). There was evidence for an association of early snus initiation with current asthma (OR 1.72; 95% CI 0.88 to 3.37 in women; OR 1.31; 95% CI 0.84 to 2.06 in men). A sensitivity analysis among participants without smoking history showed stronger estimates for all three outcomes, in both men and women, statistically significant for three or more asthma symptoms in women (OR 3.28; 95% CI 1.18 to 9.10). Finally, no consistent associations with asthma outcomes were found for starting snus after age 15 years.</p><p><strong>Conclusions: </strong>Snus initiation in puberty was associated with higher likelihood of asthma and asthma symptoms, with the highest estimates in females and those without smoking history. These results raise concerns about the health adversities of early snus initiation and emphasise the need for public health initiatives to protect young people from this tobacco product.</p>","PeriodicalId":9048,"journal":{"name":"BMJ Open Respiratory Research","volume":"11 1","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268032/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Open Respiratory Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bmjresp-2024-002401","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: To investigate the association of early snus use initiation (≤15 years of age) with asthma and asthma symptoms.
Design: Cross-sectional analysis of a population-based cohort.
Setting: Study centres in Norway, Sweden, Iceland, Denmark and Estonia, from 2016 to 2019.
Participants: 9002 male and female participants above 15 years of age of the Respiratory Health in Northern Europe, Spain and Australia study.
Main outcome measures: Current asthma and asthma symptoms.
Results: The median age of study participants was 28 years (range 15-53) and 58% were women. 20% had used snus, 29% men and 14% women. Overall, 26% of males and 14% of females using snus started ≤15 years of age. Early snus use initiation was associated with having three or more asthma symptoms (OR 2.70; 95% CI 1.46 to 5.00) and a higher asthma symptom score (β-coefficient (β) 0.35; 95% CI 0.07 to 0.63) in women. These associations were weak in men (OR 1.23; 95% CI 0.78 to 1.94; β 0.16; 95% CI -0.06 to 0.38, respectively). There was evidence for an association of early snus initiation with current asthma (OR 1.72; 95% CI 0.88 to 3.37 in women; OR 1.31; 95% CI 0.84 to 2.06 in men). A sensitivity analysis among participants without smoking history showed stronger estimates for all three outcomes, in both men and women, statistically significant for three or more asthma symptoms in women (OR 3.28; 95% CI 1.18 to 9.10). Finally, no consistent associations with asthma outcomes were found for starting snus after age 15 years.
Conclusions: Snus initiation in puberty was associated with higher likelihood of asthma and asthma symptoms, with the highest estimates in females and those without smoking history. These results raise concerns about the health adversities of early snus initiation and emphasise the need for public health initiatives to protect young people from this tobacco product.
期刊介绍:
BMJ Open Respiratory Research is a peer-reviewed, open access journal publishing respiratory and critical care medicine. It is the sister journal to Thorax and co-owned by the British Thoracic Society and BMJ. The journal focuses on robustness of methodology and scientific rigour with less emphasis on novelty or perceived impact. BMJ Open Respiratory Research operates a rapid review process, with continuous publication online, ensuring timely, up-to-date research is available worldwide. The journal publishes review articles and all research study types: Basic science including laboratory based experiments and animal models, Pilot studies or proof of concept, Observational studies, Study protocols, Registries, Clinical trials from phase I to multicentre randomised clinical trials, Systematic reviews and meta-analyses.